Quantitative Determination of Acetaminophen in Pharmaceutical Formulations Using Differential Scanning Calorimetry. Comparison with Spectrophotometric Method

In this paper our previous researches dealing with compatibility, thermoanalytical characterization, the kinetics of thermal degradation of acetaminophen, either pure or contained in some commercial pharmaceutical formulations, have found applications outlets. In a previous investigation the possible interactions between acetaminophen and four excipients contained in the commercial pharmaceutical formulations were tested. As a continuation of this research in the present study an analytical method based on differential scanning calorimetry (DSC) was applied to determine the acetaminophen content of four commercial pharmaceutical formulations. For a fifth drug it was shown that the method is not applicable owing to observed incompatibility with one of the excipients. Finally, the analytical results obtained were compared with those derived from two UV spectrophotometric methods (one, i.e., “direct method,” recommended by the Pharmacopeia and the other based on the first-order derivative UV spectra).     

A novel superdisintegrating agent made from physically modified chitosan with silicon dioxide

Disintegrants and fillers represent important excipients for immediate-release solid dosage forms in many pharmaceutical applications. A new excipient based on the coprecipitation of chitosan and silica has been achieved. The “intimate” physical association between chitosan and silica creates an insoluble, hydrophilic, highly absorbent material, consequently, resulting in superiority in water uptake, water saturation for gelling formation, and compactability among other superdisintegrants. The new excipient has an outstanding functionality that does not primarily depend on water wicking and swelling properties. In fact, it translates it into superior disintegration characteristics with improved powder flow and compaction properties. Thus, the new excipient could act as a superdisintegrant and pharmaceutical filler at the same time. Studies have shown that chitosan-silica delivers superior performance in wet granulation formulations and is the only disintegrant that is effective at all concentrations in tablet formulation.     

Tabletability of Maltodextrins and Acetaminophen Mixtures

Tabletability of five types of maltodextrin, a filler/binder excipient, was studied by testing their loading potentials with acetaminophen. The formulations consisted of excipient and acetaminophen at five different ratios and magnesium stearate at a 0.5% concentration. These mixtures were compacted employing an Integrated Compaction Research System at a constant punch velocity of 100 mm/sec. under varying applied pressures from 50 to 450 MPa. Compaction data were evaluated using the total work of compaction vs applied pressure plots whilst the post-compaction tests included the measurements of crushing force, disintegration time, and friability of the resulting tablets. Both the energy involved during the compaction of a formulation and the crushing force values of the resulting tablets decreased as the amount of the maltodextrin in a formulation was reduced. Maltodextrins exhibited adequate binding potential at acetaminophen drug loading levels of only up to twenty-five percent. The disintegration times of the tablets containing maltodextrins were generally prolonged and this was found to be due to the formation of a “gel” layer around the tablet which formed on immersion into water. The tabletability of maltodextrins were also compared to that of Fast-Flo lactose, and the compactability of these excipients were found to be similar.     

The preparation of prolonged action formulations in the form of semi solid matrix into hard gelatin capsules of oxprenolol I. Thermocap method

Abstract

The aim of this study was to obtain prolonged action by preparing semi-solid matrices (SSM) into hard gelatin capsules using Oxprenolol as a model drug.

SSM formulations were prepared by using different lipophilic and hydrophilic pharmaceutical excipients, polyethylene glycols as channeling agent in the semi solid mass and Gelucires. The release kinetic of drug from these formulations was determined and compared with the commercial preparation in the form of polymeric matrix of this drug.

Among the generally used excipients, we have found that Gelucires were the most appropriate excipients for preparation of SSMs and drug release from these dosage forms can be improved by the method mentioned above depending on quantity and type of channeling agent which was used.     

Stereoselective release behaviors of imprinted bead matrices

In this work, the stereoselective release behaviors of “low”-swelling molecularly imprinted polymer (MIP) bead matrices in pressed-coat tablet type were studied. Either R-propranolol selective MIP or S-propranolol selective MIP was combined with excipients and racemic propranolol and fabricated into the matrix. Subsequently, the release of different propranolol enantiomers from the matrices was examined. Also, the microscopic structure of the hydrated “low”-swelling MIP matrix was determined using a cryogenic scanning electron microscope in order to compare with that of the hydrated “high”-swelling MIP matrix. In vitro release profiles of the “low”-swelling matrices showed a difference in the release of enantiomers, in that the non-template isomer was released faster than the template isomer. However, in the last phase of dissolution this difference reduced and later reversed, resulting at last in the type of specificity being similar to that obtained previously with “high”-swelling MIP matrices.

n summary, MIP beads can be fashioned into matrices and incorporated into different formulations to regulate the resultant stereoselectivity. From the behaviors of stereoselective release observed in MIP matrices, we can conclude that the enantioselective-controlled delivery mechanism of MIPs via formulations depends on the relative affinity of the enantiomer for the template sites, as well as the nature of the polymer, such as hydrophobicity and swellability.     

The preparation of prolonged action formulations in the form of semi solid matrix into hard gelatin capsules of oxprenolol I. Thermocap method

The aim of this study was to obtain prolonged action by preparing semi-solid matrices (SSM) into hard gelatin capsules using Oxprenolol as a model drug.

SSM formulations were prepared by using different lipophilic and hydrophilic pharmaceutical excipients, polyethylene glycols as channeling agent in the semi solid mass and Gelucires. The release kinetic of drug from these formulations was determined and compared with the commercial preparation in the form of polymeric matrix of this drug.

Among the generally used excipients, we have found that Gelucires were the most appropriate excipients for preparation of SSMs and drug release from these dosage forms can be improved by the method mentioned above depending on quantity and type of channeling agent which was used.     

Robustness Testing of a Tablet Formulation Using Multivariate Design

ABSTRACT

A total of 45 experiments were carried out to evaluate the robustness of two similar tablet formulations—a product of two strengths—with respect to normal batch-to-batch variation of the excipients and the active pharmaceutical ingredient. The formulations consist of 10 ingredients. Because of the differing amounts of active pharmaceutical ingredients, the two formulations also differ in the amounts of two of the diluents and one of the binders. The excipients and active pharmaceutical ingredient were characterized in terms of multiple variables, and principal properties were calculated with principal component analysis. A Plackett and Burman design was applied to the principal properties. The relationships between the design factors and two responses, mean disintegration time and mean crushing strength, were evaluated by using regression methods. Both formulations were found to be robust under controlled conditions.     

Dissolution Study of Prolonged Release Morphine Tablets Using Hydrophilic Matrices

This study presents the results of “in vitro” dissolution of prolonged release morphine tablets using hydroxypropylmethylcellulose. Tablets with four different doses were elaborated and the liberation from these formulated tablets was compared with that of the only commercial pharmaceutical preparation of this type registered in the Spanish Pharmaceutical Market.

The results of the dissolution tests show that the drug was gradually released in all cases and tablets had released from 60 to 90% of its contents after 8 hours.

In the comparative study, the commercial tablets showed the fastest release. In both cases the release rate was lower when artificial intestinal fluids were used as the dissolution medium.     

Robustness testing of a tablet formulation using multivariate design

A total of 45 experiments were carried out to evaluate the robustness of two similar tablet formulations—a product of two strengths—with respect to normal batch-to-batch variation of the excipients and the active pharmaceutical ingredient. The formulations consist of 10 ingredients. Because of the differing amounts of active pharmaceutical ingredients, the two formulations also differ in the amounts of two of the diluents and one of the binders. The excipients and active pharmaceutical ingredient were characterized in terms of multiple variables, and principal properties were calculated with principal component analysis. A Plackett and Burman design was applied to the principal properties. The relationships between the design factors and two responses, mean disintegration time and mean crushing strength, were evaluated by using regression methods. Both formulations were found to be robust under controlled conditions.     

Excipients in parenteral formulations: selection considerations and effective utilization with small molecules and biologics

Excipients form a major component of pharmaceutical formulations and are classified as any ingredient other than the active ingredient which is included within the product formulation to improve drug product performance. Functional uses of excipients include improving solubility and stability, safety and efficacy, as bulking agents in lyophilized formulations, tonicity agents, and aiding in controlled or prolonged drug delivery. Parenteral formulations are sterile, pyrogen-free; free of particulate matter and by-pass the body’s natural defense mechanisms. Excipients may demonstrate a synergistic effect when combined with an active ingredient but may also lead to unwanted reactions with the drugs and packaging components. Ideal excipients are required to be considered safe, inert and multifunctional. Contrary to the past, safety of excipients needs to be well established in order for their use in the pharmaceutical formulations. Therefore, careful consideration should be given while selecting an excipient. This review article provides an overview of the excipients used exclusively in small molecule and biological parenteral products including solutions, suspensions, and lyophilized formulations, information on the possible drug-excipient and drug-packaging interactions and the regulatory requirements for the use of pharmaceutical excipients. The readers will be able to have a comprehensive understanding of the excipients used in parenteral formulations.     

Relationship Between Particle Size and Dissolution Rate of Bulk Powders and Sieving Characterized Fractions of two Qualities of Orthoboric Acid

We have carried out a study of the particle size distribution and aqueous dissolution rate of two commercially available qualities of orthoboric acid, labeled “crystal” (ABC) and “powder” (ABP). In a previous work, we have shown that the two commercial qualities of orthoboric acid chosen as model compound (“powder” and “crystal”) are related to the same crystal network in spite of their dvferent names. However, these two qualities have very different size particle distributions, as previously determined by sieving and confirmed by the present laser light scattering study. Dissolution testing is performed under sink conditions and show that the bulk ABC quality dissolves far more rapidly that the bulk ABP quality, For each quality, dissolution rates of four sieved particle size fractions (0-90 μm; 90-125 μm; 125-180 μm; 180-250 μm) were compared. Concerning the ABC quality, comparisons were also done with three other particles size fractions: 250-355 μm, 355-500 μm, and 500-710 μm. This study used the dQ/dt versus t profile. Dissolution profiles of the fractions enclosing particles with a size superior to 125 μm are very close. On the other hand, fractions enclosing particles with a size smaller than 90 μm present a different profile and a slower rate of dissolution.     

Risk assessment of supply chain for pharmaceutical excipients with AHP-fuzzy comprehensive evaluation

Abstract

As the essential components in formulations, pharmaceutical excipients directly affect the safety, efficacy, and stability of drugs. Recently, safety incidents of pharmaceutical excipients posing seriously threats to the patients highlight the necessity of controlling the potential risks. Hence, it is indispensable for the industry to establish an effective risk assessment system of supply chain. In this study, an AHP-fuzzy comprehensive evaluation model was developed based on the analytic hierarchy process and fuzzy mathematical theory, which quantitatively assessed the risks of supply chain. Taking polysorbate 80 as the example for model analysis, it was concluded that polysorbate 80 for injection use is a high-risk ingredient in the supply chain compared to that for oral use to achieve safety application in clinic, thus measures should be taken to control and minimize those risks.     

Attitudes of commercial motor vehicle drivers towards safety belts

Despite the fact that Hawaii has one of the highest seat belt use rates for passenger vehicles in the United States, and has had a mandatory seat belt use law since the 1980s, studies have shown that commercial motor vehicles (CMV) seat belt use rates are low. To better understand this phenomenon, a comprehensive survey of commercial vehicle drivers was conducted in Hawaii to ascertain attitudes and self-reported behaviors regarding seat belt use. A total of 791 drivers responded to a written questionnaire implemented at weigh stations and distributed to various trucking firms and transport centers. Approximately 67% reported that they use seat belts “always” when driving a CMV (commercial motor vehicle), yet when asked how often do other CMV drivers use seat belts, only 31% responded “always.” Interestingly, 86% of these same drivers reported that they use seat belts “always” when driving a personal vehicle. The major reason cited for non-use of belts was “frequent stops/inconvenience” (29%), and “not safety conscious” (23%). Notably, the self-reported use of safety belts is highest among operators of vans (88% said “always”), followed by buses (87% said “always”) and lowest among truck drivers (only 60% said “always”). In this paper, some of the differences between self-reported users and non-users are explored and a multivariate logit model was developed to predict the odds of belt use as a function of various factors.     

A Flow-Through Dissolution Approach to In Vivo/In Vitro Correlation of Adinazolam Release from Sustained Release Formulations

A Copley^TM fraction collector and a Disotest^TM flow-through system were coupled to provide an automatic discrete sampling flow-through dissolution system for use both in the “open-loop” and “closed-loop” mode. The system was used to investigate the release characteristics of adinazolam in sustained release formulations using a pH 1.2 simulated gastric fluid (without enzymes) dissolution medium (USP XXI). These experimental formulations are designed to provide relatively slow to rapid drug release. The dissolution effluent was analysed off-line by reverse phase HPLC to determine the adinazolam concentration at programmed timed intervals. The differential dissolution profiles produced when the system is used in the “open-loop” configuration are more discriminating in describing the release characteristics of the formulations according to the relative release rates than the “closed-loop” cumulative profiles. Using the characteristic dissolution time parameter from the Weibull function, a better correlation with in vivo bioavailability data was achieved for the data from the system in the “open-loop” mode than when it was used in the “closed-loop” mode. In the “open-loop” mode the Weibull function characteristic dissolution time parameter yielded the best quantitative correlation with a correlation coefficient of 0.92 compared to a value of 0.85 for the “closed-loop” configuration     

Multivariate Methods in the Development of a New Tablet Formulation: Optimization and Validation

In a previous study of the development of a tablet formulation approximately 100 excipients were characterized in screening experiments using multivariate design. Acceptable values for important responses were obtained with some of the formulations. The relationships between the properties of the excipients and the responses were evaluated using PLS. In this study additional experiments were performed in order to validate models obtained from the screening study and to find a formulation of suitable composition with desired tablet properties. A formulation with the desired disintegration time was found with the additional experiments and the agreement between observed and predicted values was fair for the tablets that did disintegrate. A limitation of this study was that tablets from four experiments did not disintegrate within the set time limit. The lack of agreement between observed and predicted values of these four experiments was probably due to the nature of one of the factors in the design. Considering the reduced experimental design the results are still encouraging.     

Multivariate methods in the development of a new tablet formulation: optimization and validation

In a previous study of the development of a tablet formulation approximately 100 excipients were characterized in screening experiments using multivariate design. Acceptable values for important responses were obtained with some of the formulations. The relationships between the properties of the excipients and the responses were evaluated using PLS. In this study additional experiments were performed in order to validate models obtained from the screening study and to find a formulation of suitable composition with desired tablet properties. A formulation with the desired disintegration time was found with the additional experiments and the agreement between observed and predicted values was fair for the tablets that did disintegrate. A limitation of this study was that tablets from four experiments did not disintegrate within the set time limit. The lack of agreement between observed and predicted values of these four experiments was probably due to the nature of one of the factors in the design. Considering the reduced experimental design the results are still encouraging.     

Stabilization of rasburicase and physico-chemical characterization of the resulting injectable formulation

Rasburicase (Fasturtec®/Elitek®) is a new generation of recombinant urate oxidase administred therapeutically by intravenous infusion for the prevention or treatment of hyperuricemia during chemotherapy. To ensure a long storage period, a freeze-dried formulation was developed to guarantee the molecular integrity and enzyme activity. Screening of potential excipients was the first stage of the preformulation study. The selection was based on stability results (rasburicase solution with excipient) obtained with the isoelectric focusing profiles and residual enzyme activity. The different excipients were classified as stabilising, neutral or destabilising. A stability study was then carried out on different freeze-dried formulations containing the usual bulking agents for freeze-drying, excipients with a high glass transition temperature or competitive enzyme inhibitors having a stabilising effect. A mannitol/alanine mixture in phosphate buffer was selected from these preliminary results. Finally, the optimal content of mannitol and alanine in the freeze-dried powder was determined by an experimental design study. The water content and the appearance of the “cake”, the osmolality, pH, clarity, and enzyme activity of the reconstituted solution were assessed. The formula with a mannitol/alanine ratio of 0.7 was found to be the best composition. Differential scanning calorimetry and ThermoStimulated Current technique experiments were carried out to study the amorphous phase. A glass transition temperature of about 45-50°C was found. Glassy state is known to preserve stability, which was verified by the real stability data. X-ray diffraction studies have shown that alanine is in a crystallised state and that mannitol remains amorphous. Crystallised excipients participate in forming the structure of the powder and therefore help to prevent any collapse. Amorphous mannitol creates a surrounding medium favourable to the stability of the protein.     

Selective imaging of active pharmaceutical ingredients in powdered blends with common excipients utilizing two-photon excited ultraviolet-fluorescence and ultraviolet-second order nonlinear optical imaging of chiral crystals

Second order nonlinear optical imaging of chiral crystals (SONICC) and two-photon excited fluorescence measurements [both autofluorescence and two-photon excited UV-fluorescence (TPE-UVF)] were assessed for the selective detection of APIs relative to common pharmaceutical excipients. Active pharmaceutical ingredients (APIs) compose only a small percentage of most tabulated formulations, yet the API distribution within the tablet can affect drug release and tablet stability. Complementary measurements using either UV-SONICC (266 nm detection) or TPE-UVF were shown to generate signals >50-fold more intense for a model API (griseofulvin) than those produced by common pharmaceutical excipients. The combined product of the measurements produced signals >10(4)-fold greater than the excipients studied. UV-SONICC or TPE-UVF produced greater selectivity than analogous measurements with visible-light detection, attributed to the presence of aromatic moieties within the API exhibiting strong one and two photon absorption at ~266 nm. Complementary SONICC and fluorescence measurements allowed for the sensitive detection of the three-dimensional distribution of tadalafil within a Cialis tablet to a depth of >140 μm.     

Pharmaceutical Analysis of β-Methyldigoxin in Dosage Forms Using RP-HPLC

A reversed-phase high-performance liquid chromatographic method has been developed for the assay of β-methyldigoxin in Dimekor® tablets (0.1 mg) and ampules (0.2 mg/2 mL). Quantitation of cardiac glycoside in mentioned dosage forms was carried out by the incorporation of phenacetin as an internal standard. A Varian HPLC configured with a Paltisil P10 ODS1 column was used for the separation and quantitation of β-methyldigoxin in pharmaceutical preparations. The mobile phase was acetonitrile-water 38: 62 v/v with flow rate 1.6 ml/min and UV detection was set at 220 nm. The range of linearity extended from 0.01 to 0.11 mg/mL. For the quantitative analysis of β-methyldigoxin in tablets the recovery was 100.16% and for ampules 99.50%. The excipients did not interfere with the determination of the analysed substance. The proposed method is precise and sensitive for the examination of examine the content uniformity of tablets and is in a good agreement with PH.JUG.IV (1). A spectrofluorimetric method was used for the dissolution test by the method described in USP XXII (2).